Press release
AIDS Dementia Market is projected to reach USD 2.86 billion by 2034
AIDS Dementia
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71756
AIDS dementia-also known as HIV-associated dementia-is a severe neurocognitive decline resulting from chronic HIV infection affecting the central nervous system. Although ART has significantly reduced the incidence of severe cases, milder forms of cognitive impairment remain highly prevalent, especially in low-resource regions and among patients with delayed diagnosis or poor adherence to treatment.
The market is witnessing strong demand for antiretroviral therapies with improved CNS penetration, neuroprotective agents, cognitive-enhancing drugs, and advanced diagnostic tools. Growing investment in HIV neurology research, biomarker development, and neuroimaging technologies further supports long-term market growth.
Key Market Highlights
• 2024 Market Size: USD 1.48 billion
• 2034 Market Forecast: USD 2.86 billion
• CAGR (2025-2034): 6.9%
• Largest Region: North America
• Fastest Growing Region: Asia Pacific
Market Drivers
1. Rising HIV Prevalence Worldwide
Despite improved prevention strategies, HIV continues to affect millions globally, increasing the pool of patients at risk for neurocognitive complications.
2. Longer Life Expectancy with ART
As HIV-positive individuals live longer due to highly active antiretroviral therapy (HAART), age-related neurodegeneration and chronic inflammation contribute to dementia onset.
3. Advancements in CNS-Penetrating Antiretrovirals
New formulations with better blood-brain barrier penetration reduce viral replication in the central nervous system, improving cognitive outcomes.
4. Increasing Adoption of Neurocognitive Screening
Hospitals and HIV clinics are implementing standardized cognitive assessments, rapid diagnostics, and neuroimaging tools to detect early symptoms.
5. Growing Investments in Biomarker Development
Research into inflammatory markers, viral load indicators in cerebrospinal fluid, and genetic susceptibility is paving the way for diagnostic breakthroughs.
Market Restraints
• Limited awareness of cognitive decline among HIV patients
• Incomplete viral suppression in the central nervous system even with ART
• High cost of long-term treatment and neurological monitoring
• Stigma associated with HIV leading to late diagnosis
• Lack of specialized neuro-HIV care facilities in developing regions
Market Opportunities
1. Development of Neuroprotective Therapies
Agents that reduce neuroinflammation, oxidative stress, and neural damage offer strong commercial potential.
2. Integration of AI in Cognitive Assessment
Machine learning-based tools for early detection and progression monitoring are emerging.
3. Improved CNS-penetrating ART Combinations
Optimization of regimens that effectively reduce viral reservoirs in the brain will shape future therapeutic strategies.
4. Growth in HIV Care Infrastructure in Emerging Markets
Increasing ART accessibility and better neurological services in Asia, Africa, and Latin America open new opportunities.
5. Digital Health and Remote Monitoring
Mobile cognitive testing and tele-neurology platforms support long-term patient care.
Segmentation Overview
By Treatment Type
• Antiretroviral therapy (ART)
• Cognitive-enhancing medications
• Neuroprotective and anti-inflammatory agents
• Supportive psychiatric treatments
• Behavioral therapy and rehabilitation
By Diagnosis
• Cognitive assessment tools
• MRI & CT neuroimaging
• CSF viral load tests
• Blood-based biomarkers
• Neurological examinations
By Disease Severity
• Asymptomatic neurocognitive impairment
• Mild neurocognitive disorder
• HIV-associated dementia (AIDS dementia complex)
By End User
• Hospitals
• HIV treatment centers
• Neurology clinics
• Research institutions
Explore Full Report here: https://exactitudeconsultancy.com/reports/71756/aids-dementia-market
Regional Insights
North America - Largest Market
High HIV survival rates, strong adoption of CNS-active ART, advanced neurological diagnostics, and established HIV care infrastructure support regional dominance.
Europe - Strong Adoption of Diagnostic & Monitoring Tools
Government-funded HIV programs, widespread ART access, and structured neurocognitive assessments drive stable growth.
Asia Pacific - Fastest Growing Region
Increasing HIV prevalence, improving access to ART, and rising healthcare investment in India, China, Thailand, and Southeast Asia amplify market growth momentum.
Latin America & Middle East/Africa - Significant Epidemiological Burden
High HIV incidence combined with improving treatment availability creates long-term demand for dementia-management solutions.
Competitive Landscape
Key companies operating in the AIDS Dementia Market include:
• Gilead Sciences
• ViiV Healthcare (GSK + Pfizer + Shionogi)
• AbbVie
• Merck
• Johnson & Johnson
• Cipla
• Mylan
• Bristol Myers Squibb
• Roche Diagnostics
• Quest Diagnostics
• Bio-Rad Laboratories
These companies focus on advanced ART regimens, CNS-targeted formulations, neuroinflammation therapies, and diagnostic tools.
Recent Market Developments
• Launch of new ART combinations with improved CNS penetration
• Advancements in neurocognitive biomarker research for HIV patients
• Growing use of AI-enabled cognitive screening tools
• Clinical trials evaluating neuroprotective therapies for HAND
• Strengthened HIV monitoring programs and CNS viral load assessments
Future Outlook (2025-2034)
The AIDS Dementia Market is evolving toward:
• CNS-optimized ART drug development
• Early screening and AI-driven cognitive assessment
• Neuroprotective and anti-inflammatory adjunct therapies
• Improved long-term patient monitoring in low-resource regions
• Precision approaches to manage chronic neuroinflammation
With rising global HIV prevalence and increasing emphasis on cognitive health in HIV care, the market is expected to grow from USD 1.48 billion in 2024 to USD 2.86 billion by 2034, reflecting strong long-term demand for diagnostics, therapeutics, and neurological monitoring solutions.
This report is also available in the following languages : Japanese (エイズ認知症市場), Korean (에이즈 치매 시장), Chinese (艾滋病痴呆症市场), French (Marché du SIDA et de la démence), German (AIDS-Demenz-Markt), and Italian (Mercato della demenza e dell'AIDS), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71756
Our More Reports:
Flow Assurance in Oil and Gas Market
https://exactitudeconsultancy.com/reports/74322/flow-assurance-in-oil-and-gas-market
Smart Behind-The-Ear Hearing Aid Market
https://exactitudeconsultancy.com/reports/75510/smart-behind-the-ear-hearing-aid-market
Polymer Modifiers Market
https://exactitudeconsultancy.com/reports/75519/polymer-modifiers-market
Pet Products Except Food Market
https://exactitudeconsultancy.com/reports/75896/pet-products-except-food-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AIDS Dementia Market is projected to reach USD 2.86 billion by 2034 here
News-ID: 4306760 • Views: …
More Releases from Exactitude Consultancy
Endometriosis Pain Market was valued at USD 2.95 billion in 2024 and is projecte …
Market Overview
The Endometriosis Pain Market was valued at USD 2.95 billion in 2024 and is projected to reach USD 5.10 billion by 2034, growing at a CAGR of 5.7% during the forecast period.
Endometriosis affects millions of women worldwide, causing chronic pelvic pain, infertility, menstrual abnormalities, and significant quality-of-life disruptions. Rising global awareness, earlier diagnosis, and expanding access to advanced hormonal and non-hormonal treatments are major drivers of market growth.
Demand for…
Traveler's Diarrhea Market is projected to reach USD 1.31 billion by 2034
The global Traveler's Diarrhea Market was valued at USD 700 million in 2024 and is projected to reach USD 1.31 billion by 2034, growing at a CAGR of 6.6% during the forecast period (2025-2034). Rising international travel, increasing mobility for business and tourism, expanding global air connectivity, and the prevalence of enteric pathogens in high-risk destinations are major contributors to market growth.
Download Full PDF Sample Copy of Market Report @…
Donohue Syndrome Market was valued at USD 32 million in 2024 and is expected to …
Market Overview
The Donohue Syndrome Market was valued at USD 32 million in 2024 and is expected to reach USD 56 million by 2034, growing at a CAGR of 5.9% during the forecast period.
Donohue Syndrome-also known as Leprechaunism-is an extremely rare genetic disorder caused by severe insulin receptor dysfunction leading to profound insulin resistance, growth abnormalities, and life-threatening metabolic complications.
Although the patient population is very small globally, market growth is supported…
Prosthetic Joint Infection (PJI) Market is projected to reach USD 3.58 billion b …
The global Prosthetic Joint Infection (PJI) Market was valued at USD 1.92 billion in 2024 and is projected to reach USD 3.58 billion by 2034, growing at a CAGR of 6.4% during the forecast period (2025-2034). Rising volumes of hip and knee replacement surgeries, increasing aging populations, and growing post-operative infection risk are major drivers influencing market expansion.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71752
PJI is one of…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
